S&P 500
3,351.28+2.12(+0.06%)Nasdaq
11,010.98-97.09(-0.87%)Russell 2000
1,569.18+24.56(+1.59%)
Kraig Biocraft Laboratories, Inc. (KBLB)
Chart Events
Performance Outlook
| Previous Close | 0.1300 |
| Open | 0.1310 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1200 - 0.1310 |
| 52 Week Range | 0.0900 - 0.3300 |
| Volume | 1,011,076 |
| Avg. Volume | 1,529,781 |
| Market Cap | 108.852M |
| Beta (5Y Monthly) | 0.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0070 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Kraig Biocraft Laboratories tackles biggest challenge facing Global Silk Production
As reported in the Journal of Biological Control, volume 31, viral diseases can result in total annual silk production losses of as much as 32%. Kraig Labs has developed its first immune-enhancing genetic insert, designed to create disease-resistant silkworms. The Company is now ready for its first round of transgenic creation and resistance testing.
- GlobeNewswire
Kraig Biocraft Laboratories files Application for Up-listing to the Nasdaq Capital Market
"Kraig Labs has been blessed with loyal shareholders, and we expect that moving to Nasdaq will raise the Company's visibility and expand our shareholder family." The Company’s application for uplisting, to the Nasdaq Capital Market, is subject to approval based on the ability to meet Nasdaq requirements.
- GlobeNewswire
Kraig Biocraft Laboratories Holds First Meeting of Board of Directors Elect
During this meeting, management briefed the board on the Company’s plans for 2020 expansion and growth. The Company’s expansion of its Board of Directors is intended to strengthen its corporate governance and to directly address the requirements for listing on a national exchange. The board will help the Company navigate what management expects to be a period of significant growth.
